Company facts
- Headquarters
- Cambridge, Massachusetts
- Most recent report
- 10-Q, filed Jul 29, 2026
- Incorporated
- Delaware
- Filings on record
- 1,000+ filings
- On EDGAR
- CIK 875045
- Fiscal year ends
- December
- Filer status
- Large accelerated filer
Financials 8 of 48
News 8 of 122
- 8-K Quarterly results Jul 29, 2026
- 8-K Quarterly results Jul 1, 2026
- 8-K Shareholder vote results Jun 10, 2026
- 8-K/A Current report on a material event, amended Jun 10, 2026
- 8-K Significant contract May 14, 2026
- 8-K Quarterly results Apr 29, 2026
- 8-K Quarterly results Apr 6, 2026
- 8-K Significant contract Mar 31, 2026
Prospectuses and Registrations 8 of 18
- 424B2 Prospectus supplement for an offering May 8, 2025
- FWP Free writing prospectus May 6, 2025
- 424B2 Prospectus supplement for an offering May 6, 2025
- S-3ASR Automatic shelf registration May 1, 2025
- S-8 Registration statement for an employee plan Jun 20, 2024
- POS AM Post-effective amendment to a registration Jul 6, 2022
- 424B3 Prospectus supplement for an offering May 26, 2022
- S-4 Registration statement for a merger or exchange May 17, 2022
Proxies 8 of 39
- DEFA14A Extra proxy material Apr 28, 2026
- DEF 14A Proxy statement for a shareholder vote Apr 28, 2026
- DEFA14A Extra proxy material Jun 2, 2025
- DEFA14A Extra proxy material Apr 28, 2025
- DEF 14A Proxy statement for a shareholder vote Apr 28, 2025
- DEFA14A Extra proxy material Apr 26, 2024
- DEF 14A Proxy statement for a shareholder vote Apr 26, 2024
- PRE 14A Preliminary proxy statement Apr 12, 2024
Ownership 8 of 739
- 3 Insider reported their initial holding Aug 12, 2026
- SCHEDULE 13G/A Large holder reported a passive stake, amended Aug 6, 2026
- 4 Insider reported a trade Aug 5, 2026
- 144 Notice of a proposed sale of restricted stock Aug 4, 2026
- 144 Notice of a proposed sale of restricted stock Aug 3, 2026
- 4 Insider reported a trade Jun 11, 2026
- 4 Insider reported a trade Jun 11, 2026
- 4 Insider reported a trade Jun 11, 2026
Other 8 of 34
What to read: Jun 2026 10-Q
SECSift found 2 of 10 sections worth reading, with 4 positive, 11 notable, and 4 negative flags.
- Part I New $5.4B Apellis acquisition closed; earnings and cash changes. Notable
- Management's Discussion (Item 2) Apellis acquisition closed May 2026 for $5.3B, reshaping revenue and balance sheet. Positive
- Rare disease revenue rose 10.8% to $601.7M in Q2 2026, driven by SPINRAZA high-dose and SKYCLARYS launch.
- New specialized immunology segment contributed $127.8M in Q2 2026 from SYFOVRE and EMPAVELI post-Apellis.
- ZURZUVAE revenue hit $70.8M in Q2 2026, up 52.6% year over year on continued U.S. launch momentum.
- Operating cash flow improved to $1.094B in H1 2026, up 160% from $420.2M a year ago, helped by lower tax payments.
Notable- Cost of sales rose 28.4% ($171.9M) in Q2 2026, including $112.8M in acquired inventory step-up amortization.
- R&D expense jumped 32.7% to $529.6M in Q2 2026, from $37.5M SKYCLARYS step-up and higher trial spending.
- Acquired IPR&D expense skyrocketed 251.9% to $164M in Q2 2026, mainly $100M upfront to TJ Bio.
- Apellis acquisition closed at $5.3B cash plus $4 per share CVR tied to SYFOVRE sales thresholds.
- RayThera acquisition agreed for $225M upfront and up to $775M in milestones; no prior mention.
- Diranersen missed Phase 2 CELIA primary endpoint but company plans to advance to registrational trials.
- BIIB122 discontinued after Phase 2b LUMA study failed to show benefit in early Parkinson's disease.
- Potential future milestone payments to partners rose to $7.9B, up from $6.6B in Q1 2026 due to new deals.
Negative- Section 232 100% tariff on patented pharmaceuticals effective July 31 and Sept 29, 2026, risks key products.
- MS revenue fell 13.0% to $963.3M in Q2 2026, with TECFIDERA collapsing 53% on generic erosion in Europe.
- Cash and marketable securities fell 69.7% to $1.285B from $4.248B at year-end 2025 after funding Apellis.
What changed: Jun 2026 vs. Mar 2026
About 13% of BIIB's Jun 2026 10-Q is new information. 150 paragraphs were added, 279 changed, and 58 removed. Below are the most important lines SECSift identified.
New
- Apellis acquisition closed on May 14, 2026, with $5.4B consideration. Part I
- Apellis integration restructuring plan recorded $153.2M in charges. Part I
- Ionis option exercised and $45M milestone paid for salanersen Phase 3. Part I
- RayThera acquisition announced in June 2026 for $225M upfront. Part I
- RayThera acquisition announced in June 2026 for $225M upfront; not in prior period MD&A. Item 2
- Apellis acquisition closed on May 14, 2026; prior period only described it as a proposed agreement. Item 2
- Prior quarter had zero trading arrangements; this quarter had two new 10b5-1 plans. Item 5
- Two new exhibits added: CVR Agreement (Ex. 10.1) and Credit Agreement (Ex. 10.2) from May 2026. Item 6
Removed
- Prior merger agreement (Ex. 2.1, Apellis) from March 2026 no longer listed in index. Item 6
- Prior year cited 'Reata and HI-Bio' integrations in tax risk; now replaced with generic 'acquired businesses'. Item 1A
- Prior year cited 'integration related to the pending acquisition of Apellis' as retention risk; now removed. Item 1A
Everything here comes from Biogen Inc.'s own filings on SEC EDGAR. The filing list is rechecked every hour. SECSift analysis was completed on Aug 19, 2026, from the 10-Q for Jun 2026.